United Therapeutics Corporation

249 articles with United Therapeutics Corporation

• United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference

  3/12/2019

  United Therapeutics Corporation announced that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 29th Annual Healthcare Conference in New York City.

• United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference

  3/4/2019

  United Therapeutics Corporation announced that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.

• United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results

  2/27/2019

  United Therapeutics Corporation announced its financial results for the fourth quarter and year ended December 31, 2018.

• United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019

  2/20/2019

  United Therapeutics Corporation announced that it will report its fourth quarter and annual 2018 financial results before the market opens on Wednesday, February 27, 2019.

• Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress

  2/1/2019

  United Therapeutics Corporation today announced that key data from the FREEDOM-EV study of Orenitram® extended-release tablets were shared during an oral presentation at the Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain.

• United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

  1/25/2019

  United Therapeutics Corporation announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA).

• Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

  1/25/2019

  Arena Pharmaceuticals, Inc. announced the closing of the global license agreement with United Therapeutics Corporation for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension

• United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference

  12/31/2018

  United Therapeutics Corporation announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

• SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR

  12/3/2018

  Pomerantz LLP is investigating claims on behalf of investors of United Therapeutics Corporation ("United Therapeutics" or the "Company") (NASDAQ: UTHR).  

• Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma

  11/29/2018

  United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved PrUnituxin (dinutuximab for injection), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA)

• Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag

  11/15/2018

  Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments

• 

  Arena Pharmaceuticals Snags $800 Million from United Therapeutics for a Phase III PAH Drug

  11/15/2018

  United Therapeutics bets a significant amount of money on the potential commercialization of ralinepag.

• CollPlant Announces Closing of Global Licensing and Commercialization Agreement With United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants

  11/12/2018

  Collaboration Combines CollPlant’s Proprietary rhCollagen-based BioInk Technology and United Therapeutics’ Regenerative Medicine and Organ Manufacturing Capabilities

• Nilda Mesa Joins The United Therapeutics Corporation Board Of Directors

  11/1/2018

  United Therapeutics Corporation announced today the appointment of Nilda Mesa to its Board of Directors as an independent director.

• United Therapeutics Corporation Reports Third Quarter 2018 Financial Results

  10/31/2018

  United Therapeutics Corporation today announced its financial results for the quarter ended September 30, 2018.

• United Therapeutics Corporation To Report Third Quarter 2018 Financial Results Before The Market Opens On Wednesday, October 31, 2018

  10/24/2018

  United Therapeutics Corporation announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018.

• CollPlant and United Therapeutics Announce Global Licensing and Commercialization Agreement for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplant

  10/22/2018

  Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities

• United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement

  10/16/2018

  United Therapeutics Corporation and MannKind Corporation today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension.

• United Therapeutics Corporation To Host Science Day 2018

  9/18/2018

  United Therapeutics Corporation announced today that it will host Science Day 2018 in New York City on Monday, September 24th, beginning at approximately 10:00 A.M. Eastern Time and ending at approximately 4:00 P.M. Eastern Time.

• Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate

  9/17/2018

  Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).